LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The product will be marketed by Dr. Reddy's Laboratories Inc.
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Subscribe To Our Newsletter & Stay Updated
